TB-500 Research Guide: Thymosin Beta-4, Actin & Cell Migration

What Is TB-500?

TB-500 (product code BT10; CAS 885340-08-9) is a synthetic, N-terminally acetylated heptapeptide with the sequence Ac-LKKTETQ-OH. It corresponds to residues 17–23 of the naturally occurring 43-amino-acid peptide Thymosin Beta-4 (Tβ4). This LKKTETQ segment is the central actin-binding domain of Tβ4, and it is the minimal motif shown in the published literature to retain Tβ4's actin-binding, cell-migration, and angiogenic activity.

One identity point is worth getting right up front, because vendor and marketing copy routinely garble it. TB-500 is the short fragment, not the whole protein. A very common error is to call TB-500 itself "a 43-amino-acid peptide" or to assign it Tβ4's molecular weight (~4.9 kDa). That conflates two distinct molecules. To be precise: Tβ4 is the 43-residue parent peptide (CAS 77591-33-4, MW 4,921 Da), while TB-500 is the synthetic acetylated LKKTETQ fragment (residues 17–23, MW ~889 Da) representing Tβ4's active actin-binding region.

That distinction also shapes how the evidence below should be read. Much of the foundational mechanistic and in vivo work was done with full recombinant or synthetic Tβ4, while a smaller body of work tests the short LKKTETQ peptide specifically. We flag which is which throughout, because a lot of what gets marketed as "TB-500 research" is really Tβ4 literature, with the fragment shown to recapitulate the core actin, migration, and angiogenesis functions.

Mechanism of Action: What the Research Shows

The defining mechanism of Thymosin Beta-4 — and the function its LKKTETQ motif carries — is G-actin sequestration. Tβ4 is the principal intracellular monomeric (globular) actin-sequestering peptide in most mammalian cells. It binds G-actin in a 1:1 complex, sitting in the equilibrium F-actin ↔ G-actin + Tβ4 ↔ G-actin·Tβ4. In doing so it maintains a buffered pool of unpolymerized actin monomers that a cell can rapidly mobilize into F-actin filaments when it needs to change shape or migrate.

This actin-cytoskeleton remodeling is the upstream event behind the downstream effects studied in tissue models:

• Cell migration. Tβ4 / LKKTETQ promotes migration of keratinocytes, corneal and other epithelial cells, endothelial cells, and cardiomyocytes — the cytoskeletal basis for tissue-repair models.
• Angiogenesis. Tβ4 promotes endothelial cell attachment, spreading, migration, tube formation, and aortic-ring sprouting. Critically, the seven-amino-acid actin-binding motif (LKKTETQ) — the segment that is TB-500 — was shown to be both essential for and sufficient to drive this angiogenic activity, with Notch signaling implicated in the response.
• Inflammatory-marker modulation. In corneal and other models, Tβ4 suppressed NF-κB activation in TNF-α-stimulated cells and reduced inflammatory infiltrate.
• Cell-survival signaling. Tβ4 was reported to form a complex with PINCH and integrin-linked kinase (ILK), activating Akt and enhancing cardiomyocyte survival after injury in an animal model.

One Protein, Two Functional Sub-Sites

A useful framing from the literature is that distinct Tβ4 functions map to distinct short sequences. The central LKKTETQ domain governs actin binding, cell migration, and angiogenesis — this is the TB-500 fragment. A separate N-terminal tetrapeptide, Ac-SDKP, mediates the anti-inflammatory and anti-fibrotic effects (Sosne, Qiu, Goldstein, Wheater, FASEB J, 2010). TB-500 carries the first of these sub-functions, not the second.

What the Research Literature Reports

The evidence for Thymosin Beta-4 is robust at the basic-science level but is overwhelmingly preclinical and mechanistic. The findings below are reported for context on what the published literature has observed; none of it is a use indication for research-grade material, and most positive in vivo data are for full-length Tβ4 rather than the TB-500 fragment specifically.

Mapping Tβ4's Active Sites to Short Sequences

Sosne, Qiu, Goldstein & Wheater (FASEB J, 2010; PMID 20179146) defined the biological activities of Tβ4 by the active sites in short peptide sequences. The central actin-binding domain LKKTETQ (residues 17–23, plus one residue) was associated with angiogenesis, wound healing, and cell migration, while the N-terminal Ac-SDKP reduced inflammation and fibrosis. This is the work that establishes the rationale for the TB-500 / LKKTETQ fragment as a research tool in its own right.

The Actin-Binding Motif Drives Angiogenesis

Philp, Huff, Gho, Hannappel & Kleinman (FASEB J, 2003; PMID 14500546) reported that the seven-amino-acid actin-binding motif (LKKTETQ) of Tβ4 is essential for its angiogenic activity. This directly tests the short fragment that corresponds to TB-500, and it is the strongest piece of evidence that the fragment — not just the full protein — carries the angiogenic function.

Cardiac Cell Migration and Survival

Bock-Marquette, Saxena, White, Dimaio & Srivastava (Nature, 2004; PMID 15565145) reported that Tβ4 promoted cardiac (myocardial and endothelial) cell migration and enhanced cardiomyocyte survival, forming a complex with PINCH and integrin-linked kinase (ILK) and activating Akt. After coronary ligation in mice, the peptide improved early myocyte survival and cardiac function. This is full-length Tβ4 work, not the fragment.

Corneal Wound Healing and Inflammation

Sosne, Qiu & Kurpakus-Wheater (Clin Ophthalmol, 2007; PMID 19668473) reviewed Tβ4 as a corneal wound-healing and anti-inflammatory agent, describing accelerated re-epithelialization through actin-mediated cell migration alongside suppression of NF-κB in TNF-α-stimulated cells. Broader reviews place these findings in context: Goldstein, Hannappel & Kleinman (Trends Mol Med, 2005; PMID 16099219) framed Tβ4 as an actin-sequestering protein that "moonlights" as an extracellular tissue-repair signal after injury, and Goldstein, Hannappel, Sosne & Kleinman (Expert Opin Biol Ther, 2012; PMID 22074294) compiled its structure, distribution, actin binding, and regenerative applications. The foundational identity work — that Tβ4 is indistinguishable from "Fx," the actin-sequestering factor of platelets — comes from Safer, Elzinga & Nachmias (J Biol Chem, 1991; PMID 1999398).

Reconstitution & Handling for Research

TB-500 is supplied as a lyophilized (freeze-dried) white powder, typically in sealed vials (commonly 2–10 mg). Two handling points matter for reproducible work:

• Add diluent gently — do not shake. Run the bacteriostatic water (or sterile water for a single non-stored experiment) slowly down the inside wall of the vial; do not inject the stream directly onto the powder and do not shake. Swirl or rotate gently until fully dissolved to avoid shearing or denaturing the peptide.
• Store cold and minimize freeze-thaw. Keep lyophilized powder sealed, away from light and moisture, with long-term storage at −20 °C (refrigeration is acceptable short-term). After reconstitution, store refrigerated at 2–8 °C and avoid repeated freeze-thaw cycles — aliquot if multiple uses are anticipated.

Bacteriostatic water (water with 0.9% benzyl alcohol) extends usable life versus plain sterile water, so it is the standard diluent for stored research preparations. A clear, particulate-free solution after gentle swirling indicates a clean preparation. Always pair material with a Certificate of Analysis reporting identity (mass spec) and purity (HPLC). We provide laboratory reconstitution math only — concentration in mg/mL — and no dosing or administration guidance.

TB-500 vs BPC-157

TB-500 and BPC-157 are the two peptides most often grouped together in tissue-repair research discussions, but they have different molecular origins and different proximate mechanisms. Getting the contrast precise matters.

• BPC-157 is a synthetic stable gastric pentadecapeptide — 15 amino acids (sequence GEPPPGKPADDAGLV, MW ~1,419 Da), a partial sequence of a "body protection compound" identified in gastric juice. Its studied mechanism centers on angiogenesis via the VEGFR2–Akt–eNOS pathway and nitric-oxide-system modulation, with notable proline-rich stability in gastric juice.
• TB-500 is the synthetic acetylated LKKTETQ heptapeptide (7 aa) of the 43-aa Thymosin Beta-4. Its defining mechanism is G-actin sequestration and actin-cytoskeleton remodeling driving cell migration, with angiogenic and inflammatory-marker activity attributable to that actin-binding motif.

The key difference to keep straight: different origins (a gastric protection compound vs an actin-regulating thymosin) and different proximate mechanisms (BPC-157 → VEGF/NO-driven angiogenesis and cytoprotection; TB-500 / Tβ4 → actin-monomer sequestration → migration and angiogenesis).

One popular comparison is worth a caution. The widely repeated claim that TB-500 is "longer-acting than BPC-157" (often cited as a ~10–12 h half-life) is not backed by reliable peer-reviewed pharmacokinetic data. Commercial sources contradict one another, with estimates ranging from roughly 2 h to 12 h, so this should be treated as an unverified claim rather than a fact. Both are research-use-only peptides, and both are WADA-prohibited in sport. For the full side-by-side, see our dedicated BPC-157 vs TB-500 article.

Evaluating Research-Grade TB-500 Supply

For reproducible work, the supply chain matters as much as the compound. When sourcing TB-500 for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For this peptide, the COA should report:

• HPLC purity — research-grade TB-500 should test ≥98%, ideally ≥99%.
• Mass-spec confirmation — verifying the measured mass matches the expected ~889 Da of the Ac-LKKTETQ fragment. This is also how you confirm you received the heptapeptide fragment and not a mislabeled or truncated sequence (or, conversely, full-length Tβ4 sold under the TB-500 name).
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for every research peptide we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Lyophilized Form and Cold-Chain Discipline

TB-500 should arrive as a lyophilized powder. Keep it cold and sealed until reconstitution, then reconstitute with clean bacteriostatic water. A vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

Is TB-500 the same as Thymosin Beta-4?

No — and this is the most common point of confusion. TB-500 is the synthetic acetylated heptapeptide Ac-LKKTETQ (~889 Da), corresponding to residues 17–23 of Thymosin Beta-4. Tβ4 itself is the full 43-amino-acid protein (MW 4,921 Da). TB-500 is the active actin-binding fragment, not the whole molecule. Marketing copy that calls TB-500 "a 43-amino-acid peptide" or gives it Tβ4's ~4.9 kDa weight has mixed up the two.

What is the half-life of TB-500?

There is no reliable peer-reviewed pharmacokinetic figure for the TB-500 fragment. Commonly circulated numbers (such as a 10–12 h half-life, or the claim that it is "longer-acting than BPC-157") are not supported by primary literature, and commercial sources contradict one another. We do not state a half-life as fact.

What does the LKKTETQ motif actually do?

It is the central actin-binding domain of Tβ4. It binds monomeric G-actin to buffer the unpolymerized actin pool used for cell migration, and it was specifically shown to be essential for Tβ4's angiogenic activity (Philp et al., FASEB J, 2003, PMID 14500546). It is also the segment that, on its own, makes up TB-500.

How does TB-500 differ from BPC-157?

Different origin and different mechanism. BPC-157 is a 15-amino-acid stable gastric pentadecapeptide (MW ~1,419 Da) acting mainly through VEGF / nitric-oxide-driven angiogenesis. TB-500 is a 7-amino-acid fragment of Thymosin Beta-4 acting through actin sequestration and cell migration. The popular "TB-500 lasts longer" claim has no reliable PK support. See our BPC-157 vs TB-500 comparison for the details.

What does "research-grade" mean?

It indicates the peptide is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, batch records). It is not pharmaceutical- or human-grade, is not FDA-approved, and is not for human or veterinary use. Only full-length Tβ4 (as RGN-259) has reached human clinical trials — a separate drug candidate, not this research peptide.